Preclinical models and early clinical data have suggested that PIK3CA and PTEN mutations may predict sensitivity to treatment with PI3K/AKT/mTOR inhibitors, such as everolimus, in multiple tumor types, including high-grade epithelial ovarian cancer [50,58]. Here, AKT1 is linked to neoplasm.